Discover why Denali Therapeutics Inc. earns a Strong Buy with FDA-priority drugs, solid pipeline, and a strong cash position.

Fintel reports that on December 11, 2025, Wedbush maintained coverage of Denali Therapeutics (NasdaqGS:DNLI) with a ...

As Holland America Line prepares to celebrate 80 years of exploring Alaska, the cruise line is unveiling its 2027 Cruisetour ...

This is about respecting the original stewards of the land who gave this fitting name,” she said. To pass her bill, other ...

Denali Therapeutics ( ($DNLI) ) has shared an update. On December 9, 2025, Denali Therapeutics entered into an underwriting agreement with major ...

Hypersensitivity reactions in a mouse model prompted the agency to suspend Denali’s planned Phase I development for DNL952 ...

Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa ...

Denali's validated platform, strategic pipeline, and experienced management present a compelling long-term investment opportunity. Find out why DNLI stock is a Buy.

The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...

Alaska's senior senator is again trying to move mountains to get the White House to restore Denali as the official name of ...

Denali Therapeutics filed a Registration Statement on Form S-3, which was automatically effective upon filing with the SEC on February 27, 2025, and has filed a preliminary prospectus supplement and ...

Denali Therapeutics shares were lower in premarket trading Wednesday after it priced its share offering below current trading levels. Shares were down 9.7% ahead of the morning bell at $17.75. The ...